Abstract
OBJECTIVES: The aim of this study was to investigate the occurrence of heart failure in patients treated with bisphosphonates. DESIGN: In this nationwide retrospective cohort study from Denmark, all users of bisphosphonates and raloxifene between 1996 and 2006 (n = 102 342) were included in the 'exposed' group and three age- and gender-matched subjects (n = 307.026) from the general population comprised the control group. The risk of heart failure was estimated by Cox proportional hazard analyses. RESULTS: The mean follow-up times were 2.8, 5.5 and 4.9 years for alendronate-, etidronate- and raloxifene-treated patients, respectively. The absolute risk of heart failure was 4.4% in the exposed group and 3.7% in the control group (P
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Journal of Internal Medicine |
| Vol/bind | 274 |
| Udgave nummer | 4 |
| Sider (fra-til) | 342-50 |
| Antal sider | 9 |
| ISSN | 0954-6820 |
| DOI | |
| Status | Udgivet - okt. 2013 |